dupilumab
sanofi,regeneron
['dupixent', 'dupilumab']
dupixent (dupilumab) late-breaking phase 3 data at the eadv 2022 congress showed significant improvements in signs and symptoms of prurigo nodularis 
The Headlines of Today is a World News Website, Provide World News, International Breaking News, Tech , spots and entertainment News